Pediatric posterior fossa ganglioglioma: Unique MRI features and correlation with BRAF V600E mutation status

Journal of Neuro-Oncology

Volumn 118, Issue 2, 2014, Pages 395-404

  Lindsay, Aaron J ^a   Rush, Sarah Z ^a,b   Fenton, Laura Z ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b AKRON CHILDREN'S HOSPITAL   (United States)

Author keywords

BRAF V600E; Ganglioglioma; Magnetic resonance imaging (MRI); Posterior fossa; Supratentorial

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN;

ADOLESCENT; ADULT; APOPTOSIS; ARTICLE; ATAXIA; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; DNA SEQUENCE; ELECTRONIC MEDICAL RECORD; FACIAL NERVE DISEASE; GENE MUTATION; GLIA CELL; GLIOMA; HUMAN; MORTALITY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTERIOR FOSSA GANGLIOGLIOMA; PREOPERATIVE EVALUATION; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SUPRATENTORIAL FOSSA GANGLIOGLIOMA; BRAIN; BRAIN STEM NEOPLASMS; DISEASE FREE SURVIVAL; FEMALE; GANGLIOGLIOMA; GENETICS; INFANT; INFRATENTORIAL NEOPLASMS; MALE; MUTATION; NEWBORN; NUCLEOTIDE SEQUENCE; PATHOLOGY; PATHOPHYSIOLOGY; PRESCHOOL CHILD; PROGNOSIS; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; BRAIN; BRAIN STEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; GANGLIOGLIOMA; HUMANS; INFANT; INFANT, NEWBORN; INFRATENTORIAL NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903890597     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-014-1450-1     Document Type: Article

References (38)

1. Miller DC, Lang FF, Epstein FJ (1993) Central nervous system gangliogliomas. Part 1: pathology. J Neurosurg 79(6):859-866. doi: 10.3171/jns.1993.79.6.0859
2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97-109
3. Louis DN, Wiestler OD, Ohgaki H, Cavenee WK (eds) (2007) WHO classification of tumours of the central nervous system. International Agency for Research on Cancer, Lyon
4. DeMarchi R, Abu-Abed S, Munoz D, Loch Macdonald R (2011) Malignant ganglioglioma: case report and review of literature. J Neurooncol 101(2):311-318
5. Im S-H, Chung CK, Cho B-K, Wang K-C, Yu I-K, Song IC, Cheon GJ, Lee DS, Kim N-R, Chi JG (2002) Intracranial ganglioglioma: preoperative characteristics and oncologic outcome after surgery. J Neurooncol 59(2):173-183
6. Luyken C, Blumcke I, Fimmers R, Urbach H, Wiestler OD, Schramm J (2004) Supratentorial gangliogliomas: histopathologic grading and tumor recurrence in 184 patients with a median follow-up of 8 years. Cancer 101(1):146-155
7. Rumana CS, Valadka AB (1998) Radiation therapy and malignant degeneration of benign supratentorial gangliogliomas. Neurosurgery 42(5):1038-1043
8. Zhang D, Henning TD, Zou LG, Hu LB, Wen L, Feng XY, Dai SH, Wang WX, Sun QR, Zhang ZG (2008) Intracranial ganglioglioma: clinicopathological and MRI findings in 16 patients. Clin Radiol 63(1):80-91. doi: 10.1016/j.crad.2007.06. 010
9. Lagares A, Gomez PA, Lobato RD, Ricoy JR, Ramos A, de la Lama A (2001) Ganglioglioma of the brainstem: report of three cases and review of the literature. Surg Neurol 56(5):315-322; discussion 314-322
10. Park YS, Kim D-S, Shim K-W, Kim J-H, Choi J-U (2008) Factors contributing to resectability and seizure outcomes in 44 patients with ganglioglioma. Clin Neurol Neurosurg 110(7):667-673
11. Baussard B, Di Rocco F, Garnett MR, Boddaert N, Lellouch-Tubiana A, Grill J, Puget S, Roujeau T, Zerah M, Sainte-Rose C (2007) Pediatric infratentorial gangliogliomas: a retrospective series. J Neurosurg 107(4 Suppl):286-291
12. Lang FF, Epstein FJ, Ransohoff J, Allen JC, Wisoff J, Abbott IR, Miller DC (1993) Central nervous system gangliogliomas. Part 2: clinical outcome. J Neurosurg 79(6):867-873. doi: 10.3171/jns.1993.79.6.0867
13. Zentner J, Wolf HK, Ostertun B, Hufnagel A, Campos MG, Solymosi L, Schramm J (1994) Gangliogliomas: clinical, radiological, and histopathological findings in 51 patients. J Neurol Neurosurg Psychiatry 57(12):1497-1502
14. Chan MH, Kleinschmidt-Demasters BK, Donson AM, Birks DK, Foreman NK, Rush SZ (2012) Pediatric brainstem gangliogliomas show overexpression of neuropeptide prepronociceptin (PNOC) by microarray and immunohistochemistry. Pediatr Blood Cancer 59(7):1173-1179
15. Park S-H, Kim E, Son E-I (2008) Cerebellar ganglioglioma. J Korean Neurosurg Soc 43(3):165-168
16. Michaloglou C, Vredeveld LCW, Mooi WJ, Peeper DS (2008) BRAF(E600) in benign and malignant human tumours. Oncogene 27(7):877-895
17. Sullivan RJ, Flaherty KT (2011) BRAF in melanoma: pathogenesis, diagnosis, inhibition, and resistance. J Skin Cancer 2011:423239
18. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JWC, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949-954
19. Skorokhod A, Helmbold P, Brors B, Schirmacher P, Enk A, Penzel R (2013) Automated universal BRAF state detection within the activation segment in skin metastases by pyrosequencing-based assay U-BRAF(V600). PLoS ONE 8(3):e59221. doi: 10.1371/journal.pone.0059221
20. Wan PTC, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116(6):855-867
21. Chappe C, Padovani L, Scavarda D, Forest F, Nanni-Metellus I, Loundou A, Mercurio S, Fina F, Lena G, Colin C, Figarella-Branger D (2013) Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression. Brain Pathol 23(5):574-583. doi: 10.1111/bpa.12048
22. Dahiya S, Haydon DH, Alvarado D, Gurnett CA, Gutmann DH, Leonard JR (2013) BRAF(V600E) mutation is a negative prognosticator in pediatric ganglioglioma. Acta Neuropathol 125(6):901-910. doi: 10.1007/s00401-013-1120-y
23. Donson AM, Kleinschmidt-Demasters BK, Aisner DL, Bemis LT, Birks DK, Levy JM, Smith AA, Handler MH, Foreman NK, Rush SZ Pediatric brainstem gangliogliomas show BRAF mutation in a high percentage of cases. Brain Pathol. doi: 10.1111/bpa.12103
24. Dougherty MJ, Santi M, Brose MS, Ma C, Resnick AC, Sievert AJ, Storm PB, Biegel JA (2010) Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neurooncology 12(7):621-630
25. Koelsche C, Wohrer A, Jeibmann A, Schittenhelm J, Schindler G, Preusser M, Lasitschka F, von Deimling A, Capper D Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. Acta Neuropathol 125(6):891-900. doi: 10.1007/s00401-013-1100-2
26. MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal C, Luongo L, Emery CM, Baker AC, Philips J, Goff DJ, Fiorentino M, Rubin MA, Polyak K, Chan J, Wang Y, Fletcher JA, Santagata S, Corso G, Roviello F, Shivdasani R, Kieran MW, Ligon KL, Stiles CD, Hahn WC, Meyerson ML, Garraway LA (2009) Profiling critical cancer gene mutations in clinical tumor samples. PLoS ONE 4(11):e7887. doi: 10.1371/journal.pone.0007887
27. Myung JK, Cho H, Park CK, Kim SK, Lee SH, Park SH (2012) Analysis of the BRAF(V600E) mutation in central nervous system tumors. Transl Oncol 5(6):430-436
28. Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, Schmieder K, Wesseling P, Mawrin C, Hasselblatt M, Louis DN, Korshunov A, Pfister S, Hartmann C, Paulus W, Reifenberger G, von Deimling A (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121(3):397-405
29. Rush S, Foreman N, Liu A (2013) Brainstem ganglioglioma successfully treated with vemurafenib. J Clin Oncol 31(10):e159-e160. doi: 10.1200/JCO.2012.44.1568
30. Johnson JH, Hariharan S, Berman J, Sutton LN, Rorke LB, Molloy P, Phillips PC (1997) Clinical outcome of pediatric gangliogliomas: ninety-nine cases over 20 years. Pediatr Neurosurg 27(4):203-207
31. Ramos A, Hilario A, Lagares A, Salvador E, Perez-Nunez A, Sepulveda J (2013) Brainstem gliomas. Semin Ultrasound CT MRI 34(2):104-112. doi: 10.1053/j.sult.2013.01.001
32. Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, Kageshita T, Ono T, Albertson DG, Pinkel D, Bastian BC (2003) Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 95(24):1878-1890
33. Kim SJ, Lee KE, Myong JP, Park JH, Jeon YK, Min HS, Park SY, Jung KC, Koo do H, Youn YK (2012) BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg 36(2):310-317. doi: 10.1007/s00268-011-1383-1
34. Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK, Lee YJ, Kim KW, Hahn SK, Youn YK, Kim KH, Cho BY, Park do J (2012) The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 118(7):1764-1773. doi: 10.1002/cncr.26500
35. Tufano RP, Teixeira GV, Bishop J, Carson KA, Xing M (2012) BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine (Baltim) 91(5):274-286. doi: 10.1097/MD.0b013e31826a9c71
36. Nicolaides TP, Li H, Solomon DA, Hariono S, Hashizume R, Barkovich K, Baker SJ, Paugh BS, Jones C, Forshew T, Hindley GF, Hodgson JG, Kim JS, Rowitch DH, Weiss WA, Waldman TA, James CD (2011) Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res 17(24):7595-7604. doi: 10.1158/1078-0432.CCR-11-1456
37. Schiffman JD, Hodgson JG, VandenBerg SR, Flaherty P, Polley M-YC, Yu M, Fisher PG, Rowitch DH, Ford JM, Berger MS, Ji H, Gutmann DH, James CD (2010) Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res 70(2):512-519
38. Safaee Ardekani G, Jafarnejad SM, Tan L, Saeedi A, Li G (2012) The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS ONE 7(10):e47054. doi: 10.1371/journal.pone.0047054